Metastatic Castration-Resistant Prostate Cancer: Case 1 - Episode 3

Daniel P. Petrylak, MD: Efficacy Data's Role in Sequencing Therapies in mCRPC

May 26, 2015


CASE 1: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Robert C. is a 63-year-old physical education teacher and high school wrestling coach from Savannah, Georgia

In May 2007, patient presented to his PCP and received routine screening for prostate cancer.

Patient’s PSA level was 6.2 ng/mL

Digital rectal examination and subsequent CT scan revealed the presence of prostate adenocarcinoma T2bN0M0, Gleason 6 (2+4), classified as intermediate risk

Patient underwent radical prostatectomy and adjuvant radiotherapy in June 2007

Patient’s prior medical history is notable for abdominal aortic aneurysm surgery in 2002 and hypertension (well controlled on current therapy)

His liver function tests were unremarkable

In July 2010, after approximately 3 years, the patient returned to his PCP for a routine physical, and an increase in PSA to 9.7 ng/mL was detected; he was asymptomatic.

Bone scan in August 2010 was negative

Androgen deprivation therapy (ADT) was initiated in August 2010 with goserelin; the patient’s PSA subsequently decreased to 0.5 ng/mL

In September 2012, after approximately 2 years, the patient’s PSA began to rise to 2.0 ng/mL; testosterone level was 19 ng/dL

Oral bicalutamide was added to his ADT; he continued to be asymptomatic

In April 2013, the patient presented to his PCP complaining of lower back pain and moderate to severe fatigue; his PSA had increased to 3.7 ng/mL

Bone scan revealed the presence of diffuse bone lesions in the lumbar and sacral vertebral bodies